A Female With Systemic Lupus Erythematosus and Streptococcal Pneumonia Treated With Intravenous Immunoglobulins (Ivig)

Vaillant, Angel Justiz

doi:10.20944/preprints202009.0544.v1

Cited by 9 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many patients experienced symptoms of myositis at 77% and alopecia at 60%. Pleurisy accounted for 43% of patients, while low complement and leukopenia values were 60% and 35%, respectively [5-7]. In the control group those manifestations accounted for less that 5%.…”

Section: Resultsmentioning

confidence: 99%

Cytokines (IL-17, IL-23 and IL-33) in Systemic lupus erythematosus in Trinidad and Tobago

Justiz-Vaillant¹,

Nobee

2020

Preprint

View full text Add to dashboard Cite

The systemic lupus erythematosus (SLE) is the greatest manifestation of autoimmunity. It is characterized by the presence of cytokines, including type I and II interferons, interleukin-6 (IL-6), IL-1, and tumor necrosis factor-alpha (TNF-α), the immunomodulatory cytokines like IL-10 and TGF-β, be essential players in SLE. Additionally, T-cell-derived cytokines like IL-17A, IL-21, and IL-2 are dysregulated in SLE. In this paper, a prospective cross-sectional and observational study was done. It was measured the levels of 3 essential cytokines in SLE: IL-17A, IL-23, and IL-33 using three enzyme-linked immunosorbent assays (ELISA). Thirty (30) patients attending the rheumatoid clinic at one of the major regional hospitals in the Caribbean region were recruited. Mostly females above the childbearing age give their consent to be included in the study and other 30 healthy patients were used a control. Of all the SLE patients, 15 (50%) patients were of Afro-Caribbean descent, 12 (40%) of patients were of Indo-Caribbean descent, and 3 (10%) of patients were of mixed descent. Nineteen (63%) healthy controls were females, and 11 (37%) were males. The results showed that serum IL-17A and IL-23 were more significantly higher in SLE patients than controls (P<0.01); however, there was no statistically significant difference between IL-33 levels between SLE patients and healthy controls. The study showed no correlation between serum IL-17A and IL-23 in SLE patients as judged by the result of the Pearson correlation coefficient (r=0.308, p>0.05). It also showed that serum IL-17A and IL-23 levels positively correlate to the SLE disease activity index 2000 score (SLEDAI score). Nevertheless, IL-33 levels show no correlation with the SLEDAI score. In this study, higher cytokines were reported mostly in patients between the ages of 25 to 30-year-old and Afro-Caribbean descent.

show abstract

Section: Resultsmentioning

confidence: 99%

Cytokines (IL-17, IL-23 and IL-33) in Systemic lupus erythematosus in Trinidad and Tobago

Justiz-Vaillant¹,

Nobee

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…SLE is a complex, multisystem autoimmune disease characterised by a wide spectrum of clinical manifestations, and excessive immunological and laboratories abnormalities (ie, autoantibody production, complement activation and immune-complex deposition). SLE can lead to multiple organ damage, and is primarily affecting women with peak incidence occurs during childbearing age years 1 2. Despite advances in treatment, mortality among patients with SLE remains high with geographical variations 3…”

Section: Introductionmentioning

confidence: 99%

Human leucocyte antigens profiling in Malay female patients with systemic lupus erythematosus: are we the same or different?

et al. 2022

View full text Add to dashboard Cite

ObjectiveSLE is a heterogeneous autoimmune disease, in terms of clinical presentation, incidence and severity across diverse ethnic populations. We investigated the human leucocyte antigens (HLA) profile (ie, HLA-A, HLA-B and HLA-C, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-DPB1) in Malaysian Malay female patients with SLE and determined the generalisability of the published HLA risk factors across different ethnic populations globally including Malaysia.MethodsOne hundred Malay female patients with SLE were recruited between January 2016 and October 2017 from a nephrology clinic. All patients were genotyped for HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-DPB1 alleles using PCR sequence-specific oligonucleotides method on Luminex platform. A total of 951 HLA genotyped population-based Malay control subjects was used for association testing by means of OR with 95% CIs.ResultsOur findings convincingly validated common associations between HLA−A*11 (OR=1.65, p=3.36×10−3, corrected P (Pc)=4.03×10−2) and DQB1*05:01 (OR=1.56, p=2.02×10−2, Pc=non−significant) and SLE susceptibility in the Malay population. In contrast, DQB1*03:01 (OR=0.51, p=4.06×10−4, Pc=6.50×10−3) were associated with decreased risk of SLE in Malay population. Additionally, we also detected novel associations of susceptibility HLA genes (ie, HLA-B*38:02, DPA1*02:02, DPB1*14:01) and protective HLA genes (ie, DPA1*01:03). When comparing the current data with data from previously published studies from Caucasian, African and Asian populations, DRB1*15 alleles, DQB1*03:01 and DQA1*01:02 were corroborated as universal susceptibility and protective genes.ConclusionsThis study reveals multiple HLA alleles associated with susceptibility and protection against risk of developing SLE in Malay female population with renal disorders. In addition, the published data from different ethnic populations together with our study further support the notion that the genetic effects from association with DRB1*15:01/02, DQB1*03:01 and DQA1*01:02 alleles are generalised to multiple ethnic populations of Caucasian, African and Asian descents.

show abstract

“…SLE treatment is directed at the suppression of disease activity and the prevention of irreversible organ damage, leading to survival rates between 85% to 90% during the first 10 years [ 8 ], but iatrogenic damage is a major clinical issue in SLE, mostly related to long-term use of glucocorticoids (GCs) [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Bone Involvement in Systemic Lupus Erythematosus

Rella

Rotondo

Altomare

et al. 2022

IJMS

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a wide variability of clinical manifestations due to the potential involvement of several tissues and internal organs, with a relapsing and remitting course. Dysregulation of innate and adaptive immune systems, due to genetic, hormonal and environmental factors, may be responsible for a broad spectrum of clinical manifestations, affecting quality of life, morbidity and mortality. Bone involvement represents one of the most common cause of morbidity and disability in SLE. Particularly, an increased incidence of osteoporosis, avascular necrosis of bone and osteomyelitis has been observed in SLE patients compared to the general population. Moreover, due to the improvement in diagnosis and therapy, the survival of SLE patient has improved, increasing long-term morbidities, including osteoporosis and related fractures. This review aims to highlight bone manifestations in SLE patients, deepening underlying etiopathogenetic mechanisms, diagnostic tools and available treatment.

show abstract

A Female With Systemic Lupus Erythematosus and Streptococcal Pneumonia Treated With Intravenous Immunoglobulins (Ivig)

Cited by 9 publications

References 9 publications

Cytokines (IL-17, IL-23 and IL-33) in Systemic lupus erythematosus in Trinidad and Tobago

Cytokines (IL-17, IL-23 and IL-33) in Systemic lupus erythematosus in Trinidad and Tobago

Human leucocyte antigens profiling in Malay female patients with systemic lupus erythematosus: are we the same or different?

Bone Involvement in Systemic Lupus Erythematosus

Contact Info

Product

Resources

About